Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders

• Research unit: INNOSUISSE
• Project number: 14785.1 PFLS-LS

Short description (German)

Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders

Short description (English)

Characterization and optimization of a novel drug class based on allosteric modulation for applications in neurodegenerative and psychiatric disorders

Abstract (German)

The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.

Abstract (English)

The objective of this project is the characterization and optimization of a new class of drug candidates based on allosteric modulation for neurodegenerative and psychiatric diseases. Specifically, allosteric modulators targeting Group III of metabotropic glutamate receptors will be assessed in animal models replicating human Parkinson‟s disease (mGluR4), whereas electrophysiological studies will be carried out on allosteric modulators targeting mGluR4 and mGluR7, in order to investigate their role in modulating synaptic transmission and further characterize their potential therapeutic application in neurodegenerative diseases and anxiolytic disorders. Project results will contribute in the selection of the best candidate compounds for clinical development.